General Information of Drug Therapeutic Target (DTT) (ID: TT8ZLTI)

DTT Name Programmed cell death 1 ligand 1 (PD-L1)
Synonyms hPD-L1; Programmed death ligand 1; PDL1; PDCD1LG1; PDCD1L1; PDCD1 ligand 1; B7H1; B7-H1; B7 homolog 1
Gene Name CD274
DTT Type
Successful target
[1]
BioChemical Class
Immunoglobulin
UniProt ID
PD1L1_HUMAN
TTD ID
T99948
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Sequence
MRIFAVFIFMTYWHLLNAFTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEME
DKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGG
ADYKRITVKVNAPYNKINQRILVVDPVTSEHELTCQAEGYPKAEVIWTSSDHQVLSGKTT
TTNSKREEKLFNVTSTLRINTTTNEIFYCTFRRLDPEENHTAELVIPELPLAHPPNERTH
LVILGAILLCLGVALTFIFRLRKGRMMDVKKCGIQDTNSKKQSDTHLEET
Function
As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10). Plays a critical role in induction and maintenance of immune tolerance to self.
KEGG Pathway
Cell adhesion molecules (CAMs) (hsa04514 )
Reactome Pathway
PD-1 signaling (R-HSA-389948 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
6 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Atezolizumab DMMF8U0 Non-small-cell lung cancer 2C25 Approved [2]
Avelumab DMSZLJR Merkel cell carcinoma 2C34 Approved [3]
Bavencio DMU9C8F Merkel cell carcinoma 2C34 Approved [4]
Durvalumab DM4PVDY Urothelial carcinoma 2C92.0 Approved [5]
RG-7446 DM69XMQ Urothelial carcinoma 2C92.0 Approved [1]
Sugemalimab DMH5YQ3 Non-small-cell lung cancer 2C25 Approved in China [6]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 Approved Drug(s)
35 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
A167 DME00MM Nasopharyngeal carcinoma 2B6B Phase 3 [7]
CS1001 DMSY0NE Non-small-cell lung cancer 2C25 Phase 3 [8]
KN046 DMSDBPG Non-small-cell lung cancer 2C25.Y Phase 3 [9]
MEDI4736 DM5X849 Solid tumour/cancer 2A00-2F9Z Phase 3 [10]
MPDL-3280A DM9K3LM Melanoma 2C30 Phase 3 [11]
Bintrafusp alfa DMB9LRJ Non-small-cell lung cancer 2C25 Phase 2 [12]
CX-072 DMVZT2I Advanced malignancy 2A00-2F9Z Phase 2 [13]
INCB86550 DMJN9PU Solid tumour/cancer 2A00-2F9Z Phase 2 [14]
KN035 DMKLMG6 Pleomorphic sarcoma 2B54 Phase 2 [15]
M7824 DMJCULI Solid tumour/cancer 2A00-2F9Z Phase 2 [16]
Pidilizumab DMMO46E Diffuse large B-cell lymphoma 2A81 Phase 2 [17]
BGB-A333 DM5VG6S Solid tumour/cancer 2A00-2F9Z Phase 1/2 [18]
GS-4224 DM1GE67 Solid tumour/cancer 2A00-2F9Z Phase 1/2 [19]
NM21-1480 DMDNJP5 Advanced solid tumour 2A00-2F9Z Phase 1/2 [20]
A337 DMXWFP2 Aggressive cancer 2A00-2F9Z Phase 1 [7]
ALPN-202 DMTD4EF Solid tumour/cancer 2A00-2F9Z Phase 1 [21]
Anti-PD-L1 DM0UL47 Human immunodeficiency virus-1 infection 1C62 Phase 1 [22]
Anti-PD-L1 CSR T cells DMWIJL1 Glioblastoma multiforme 2A00.0 Phase 1 [23]
BMS-986189 DMXU5FK N. A. N. A. Phase 1 [15]
C-Met/PD-L1 CAR-T Cell DMHBNKP Hepatocellular carcinoma 2C12.02 Phase 1 [24]
CA-170 DMOUHR4 Lymphoma 2A80-2A86 Phase 1 [16]
Cosibelimab DMULBZM Non-small-cell lung cancer 2C25 Phase 1 [25]
FAZ053 DM71HLX Advanced cancer 2A00-2F9Z Phase 1 [13]
FS118 DM0QH9K Advanced cancer 2A00-2F9Z Phase 1 [15]
GEN1046 DMEWRNZ Solid tumour/cancer 2A00-2F9Z Phase 1 [26]
IBI318 DMB83V4 Non-small-cell lung cancer 2C25 Phase 1 [27]
INBRX-105 DM2FH10 Solid tumour/cancer 2A00-2F9Z Phase 1 [28]
KD033 DMTYNRB Solid tumour/cancer 2A00-2F9Z Phase 1 [29]
LY3300054 DMOV2ML Advanced malignancy 2A00-2F9Z Phase 1 [16]
LY3415244 DM5QO1A Solid tumour/cancer 2A00-2F9Z Phase 1 [30]
MCLA-145 DM8CGUV Lymphoma 2A80-2A86 Phase 1 [31]
MSB2311 DMH8VXE Advanced malignancy 2A00-2F9Z Phase 1 [15]
PD-L1 t-haNK DMLJHM2 Solid tumour/cancer 2A00-2F9Z Phase 1 [32]
PF-07257876 DM0E2SW Non-small-cell lung cancer 2C25 Phase 1 [33]
TAK-252 DM1AKNI Solid tumour/cancer 2A00-2F9Z Phase 1 [34]
------------------------------------------------------------------------------------
⏷ Show the Full List of 35 Clinical Trial Drug(s)
2 Patented Agent(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID30107136-Compound-Example1 DMY37VQ Hepatitis DB97.Z Patented [35]
PMID30107136-Compound-Example2 DM9HMB4 Hepatitis DB97.Z Patented [35]
------------------------------------------------------------------------------------
10 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
CA-327 DMP5OSK N. A. N. A. Investigative [15]
PMID30247903-Compound-General structure10 DMOA1Y7 N. A. N. A. Investigative [15]
PMID30247903-Compound-General structure12 DMA3ZPH N. A. N. A. Investigative [15]
PMID30247903-Compound-General structure5 DM7LUI2 N. A. N. A. Investigative [15]
PMID30247903-Compound-General structure6 DMHQ6C3 N. A. N. A. Investigative [15]
PMID30247903-Compound-General structure7 DM9QMA2 N. A. N. A. Investigative [15]
PMID30247903-Compound-General structure8 DMLMYE0 N. A. N. A. Investigative [15]
PMID30247903-Compound-General structure9 DMBR7A6 N. A. N. A. Investigative [15]
YH010 DMA1T66 Aggressive cancer 2A00-2F9Z Investigative [36]
YH011 DM3JEEU Aggressive cancer 2A00-2F9Z Investigative [37]
------------------------------------------------------------------------------------
⏷ Show the Full List of 10 Investigative Drug(s)

Molecular Expression Atlas (MEA) of This DTT

Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This DTT
Disease Name ICD 11 Studied Tissue p-value Fold-Change Z-score
Bladder cancer 2C82 Bladder tissue 4.38E-07 0.37 2.1
------------------------------------------------------------------------------------

References

1 PD-1 as a potential target in cancer therapy. Cancer Med. 2013 October; 2(5): 662-673.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
3 Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res. 2015 Oct;3(10):1148-57.
4 ClinicalTrials.gov (NCT03403777) Avelumab in Refractory Testicular Germ Cell Cancer.. U.S. National Institutes of Health.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 Sugemalimab: First Approval. Drugs. 2022 Apr;82(5):593-599.
7 Clinical pipeline report, company report or official report of Klus Pharma
8 GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy. Transl Lung Cancer Res. 2020 Oct;9(5):2008-2015.
9 Clinical pipeline report, company report or official report of Alphamab Oncology.
10 National Cancer Institute Drug Dictionary (drug id 740856).
11 Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol. 2014 May 10; 5(2): 39-47.
12 Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. J Thorac Oncol. 2020 Jul;15(7):1210-1222.
13 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
14 National Cancer Institute Drug Dictionary (drug name INCB086550).
15 Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
16 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
17 PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother. 2011 Jun;34(5):409-18.
18 Clinical pipeline report, company report or official report of BeiGene.
19 Clinical pipeline report, company report or official report of Gilead Sciences.
20 Clinical pipeline report, company report or official report of Numab Therapeutics.
21 Clinical pipeline report, company report or official report of Alpine Immune Sciences.
22 Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012 Jun 28;366(26):2455-65.
23 ClinicalTrials.gov (NCT02937844) Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme
24 ClinicalTrials.gov (NCT03672305) Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC
25 Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
26 Clinical pipeline report, company report or official report of Genmab.
27 Clinical pipeline report, company report or official report of Innovent.
28 Clinical pipeline report, company report or official report of Inhibrx.
29 Clinical pipeline report, company report or official report of Kadmon.
30 Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors. Clin Cancer Res. 2021 May 15;27(10):2773-2781.
31 Clinical pipeline report, company report or official report of Merus.
32 ClinicalTrials.gov (NCT04050709) QUILT 3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers. U.S. National Institutes of Health.
33 ClinicalTrials.gov (NCT04881045) A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07257876 IN PATIENTS WITH ADVANCED OR METASTATIC TUMORS. U.S.National Institutes of Health.
34 Clinical pipeline report, company report or official report of Shattuck Labs.
35 A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
36 Clinical pipeline report, company report or official report of Biocytogen
37 Clinical pipeline report, company report or official report of Biocytogen